Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants ...
A new class of protein drugs has been shown in vitro to maintain inhibition against Covid-19 variants of concern known to date, according to Molecular Partners AG (NYSE: MolN), a clinical-stage biotech company which develops new therapeutics.
Source: apnews.comPublished on 2021-10-20
Related news
- UK Energy Performance : B prepared for new 2030 MEES ratings | Hogan Lovells
- Transforming public health through social innovation
- Patient Safety Movement Foundation Announces Winners of 2020 Humanitarian Awards
- Redirecting to Patient Safety Movement Foundation Announces Winners of 2020 Humanitarian Awards
- The digital landscape and technical opportunities
- The EU and Japan : Strategic Partners in the Indo - Pacific
- Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV - WHO Conference